Notícias
Apenas manchetes de alto sinal - eventos macro, resultados, M&A, regulatório. Listicles e clickbait de analistas filtrados por padrão. Atualizado a cada hora.
109last 24h
3127last 7d
511● bullish (7d)
313● bearish (7d)
227publishers
Clinical Trials Arena94d agoneutral
MSD and Gilead scrap Phase III Trodelvy-Keytruda study on lacklustre interim dataGuruFocus.com95d agoneutral
Compass Pathways PLC (CMPS) (Q2 2026) Earnings Call Highlights: Strong Cash Position and NDA ...Simply Wall St.95d agoneutral
Gilead (GILD) Faces HIV Drug Access Criticism From AIDS Healthcare FoundationSimply Wall St.95d agoneutral
The Bull Case For Gilead Sciences (GILD) Could Change Following Deeper 2026 Losses Amid HIV, Oncology GrowthBioPharma Dive95d agoneutral
Earnings roundup: Gilead’s ‘uncertain’ future, Pfizer’s crossroads and Merck’s PCSK9 launchGuruFocus.com96d agoneutral
Gilead Sciences Inc (GILD) (Q2 2026) Earnings Call Highlights: PrEP Sales Double to $1B, HIV ...The Wall Street Journal96d agoneutral
Gilead Sciences Swings to Loss on R&D Costs as HIV-Drug Sales Lift RevenueBarrons.com96d agoneutral
Gilead Posts a Loss on Acquisitions but Revenue Tells a Bigger StoryInvestor's Business Daily96d agobearish
Why Gilead's High-Profile HIV Drug Might Have To Play Catch-UpInsider Monkey96d agoneutral
Could Gilead Sciences (GILD) Have a Major HIV Growth Engine in Yeztugo?MarketBeat97d agoneutral
Merck Spotlights Weekly HIV Treatment, Monthly PrEP as $5B Growth Opportunity